Mirae Asset Global Investments
CERE

Mirae Asset Global Investments’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Mirae Asset Global Investments’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,526
Closed -$876K – 2663
2024
Q1 		$876K Sell
31,526
-4,837
-13% -$203K ﹤0.01% 1609
2023
Q4 		$1.54M Buy
36,363
+2,117
+6% +$60.8K ﹤0.01% 1382
2023
Q3 		$748K Buy
34,246
+358
+1% +$8.96K ﹤0.01% 1682
2023
Q2 		$1.08M Buy
33,888
+1,116
+3% +$34.3K ﹤0.01% 1525
2023
Q1 		$799K Buy
32,772
+7,963
+32% +$234K ﹤0.01% 1662
2022
Q4 		$782K Buy
24,809
+2,162
+10% +$61K ﹤0.01% 1638
2022
Q3 		$640K Buy
22,647
+6,970
+44% +$208K ﹤0.01% 1729
2022
Q2 		$414K Buy
+15,677
New +$445K ﹤0.01% 1845

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Mirae Asset Global Investments's CERE Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 31,526 shares — an estimated $876K sold.

Mirae Asset Global Investments first reported a position in CERE in Q2 2022 and held it in 8 quarters. The position peaked at $1.54M in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 31,526 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $876K.
  • Mirae Asset Global Investments first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 8 quarters.
  • Mirae Asset Global Investments's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.54M in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.